The biotech company Biovica, inventors of DiviTum™ and SimplicityBio creators of the Biomarker Optimization Software System (BOSS), have agreed to collaborate to discover and improve multi-biomarker panels for faster and better evaluation of cancers and new oncology drugs. Together the companies offer a unique solution to correlate efficacy of novel drugs with patient outcome and impact on cell proliferation rate.
This solution offers the opportunity for drug developers to obtain crucial data to accelerate discovery and development with informed decisions for increased success rate. Biovica has developed DiviTum™, a highly sensitive assay measuring cell proliferation rates for prediction and monitoring of cell cycle regulating oncology drugs. SimplicityBio has developed BOSS enabling discovery and improvement of biomarker panels from multi-type data sets, linking clinical outcomes to biomarkers. The combined technologies from the two companies will enable to test hypotheses and biomarker combinations for better and faster evaluation of novel oncology drug candidates in pre-clinical and early clinical studies.
“The capacity to stratify patients and precisely monitor cell proliferation is a new step in accelerating oncology drugs development. Combining our expertise offers this exciting perspective to our customers.“ says Miguel Barreto, CEO at SimplicityBio.
Anders Rylander, CEO at Biovica: “Our collaboration will enable our partners to make more informed decisions earlier in their development process, linking biomarkers to drug efficacy and cell proliferation all the way from early development to clinical trials. We are looking forward to offer this solution to our partners.”
FACTS ABOUT SIMPLICITYBIO
SimplicityBio is a Swiss biomarker panel discovery company. SimplicityBio’s focus is to enable pharmaceutical companies design clinical trials with improved patient stratification, define the best responder population to a certain drug and minimise risks of diagnostic companies by increasing the accuracy of their diagnostic tests. SimplicityBio uses its proprietary software platform to provide services and find the best panel of biomarkers in terms of size, accuracy and interpretability to be used for stratification, diagnostics or companion diagnostics thus reducing the cost and increasing success. SimplicityBio also co-develops diagnostic tests with industrial partners.
See also www.simplicitybio.com
FACTS ABOUT BIOVICA AND DIVITUM™
Biovica is a bio-diagnostic company focused on providing improved diagnostics, predictive data and monitoring of cancer patient under treatment. Biovica has developed DiviTum™, a highly sensitive assay for measuring cell proliferation. Since one of the most fundamental characteristics of cancer is uncontrolled and in-creased cell growth, DiviTum™ enables valuable prediction capability and monitoring of compounds regulating cell proliferation and the cell cycle. Biovica is ISO 13485 certified for Quality Management Systems and DiviTum™ is CE labeled and MPA registered.
Matthew G. Hall, CSO & co-founder
Tel +41 (0)76 241 03 25
Mattias Bergqvist, Marketing Director
Tel +46 (0)18 44 44 832
Mobile +46 (0)709 154 380